NANOBIOTIX (NANO.PA)

FR0011341205 - Common Stock

2.84  -0.12 (-3.99%)

Fundamental Rating

1

Taking everything into account, NANO scores 1 out of 10 in our fundamental rating. NANO was compared to 74 industry peers in the Biotechnology industry. Both the profitability and financial health of NANO have multiple concerns. NANO is quite expensive at the moment. It does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

NANO had negative earnings in the past year.
In the past year NANO has reported a negative cash flow from operations.
NANO had negative earnings in each of the past 5 years.
In the past 5 years NANO always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -42.28%, NANO is doing worse than 60.61% of the companies in the same industry.
Industry RankSector Rank
ROA -42.28%
ROE N/A
ROIC N/A
ROA(3y)-61.3%
ROA(5y)-59.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NANO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

1

2. Health

2.1 Basic Checks

NANO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NANO has more shares outstanding
The number of shares outstanding for NANO has been increased compared to 5 years ago.
The debt/assets ratio for NANO has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -3.98, we must say that NANO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.98, NANO is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.98
ROIC/WACCN/A
WACC9.24%

2.3 Liquidity

A Current Ratio of 1.75 indicates that NANO should not have too much problems paying its short term obligations.
NANO has a Current ratio of 1.75. This is in the lower half of the industry: NANO underperforms 66.67% of its industry peers.
A Quick Ratio of 1.75 indicates that NANO should not have too much problems paying its short term obligations.
NANO's Quick ratio of 1.75 is on the low side compared to the rest of the industry. NANO is outperformed by 63.64% of its industry peers.
Industry RankSector Rank
Current Ratio 1.75
Quick Ratio 1.75

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 54.64% over the past year.
NANO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 203.88% yearly.
EPS 1Y (TTM)54.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.5%
Revenue 1Y (TTM)N/A
Revenue growth 3Y743.98%
Revenue growth 5Y203.88%
Sales Q2Q%182.08%

3.2 Future

The Earnings Per Share is expected to grow by 5.95% on average over the next years.
Based on estimates for the next years, NANO will show a quite strong growth in Revenue. The Revenue will grow by 10.63% on average per year.
EPS Next Y5.24%
EPS Next 2Y-0.06%
EPS Next 3Y14.3%
EPS Next 5Y5.95%
Revenue Next Year-32.11%
Revenue Next 2Y-27.72%
Revenue Next 3Y31.06%
Revenue Next 5Y10.63%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NANO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NANO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

NANO's earnings are expected to grow with 14.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.06%
EPS Next 3Y14.3%

0

5. Dividend

5.1 Amount

NANO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NANOBIOTIX

EPA:NANO (1/15/2025, 10:04:26 AM)

2.84

-0.12 (-3.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2024-11-10
Earnings (Next)N/A N/A
Inst Owners26.52%
Inst Owner ChangeN/A
Ins Owners0.3%
Ins Owner ChangeN/A
Market Cap134.63M
Analysts87.27
Price Target11.6 (308.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.9%
PT rev (3m)-1.94%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-14.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)13.21%
Revenue NY rev (3m)13.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.74
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.63
BVpS-0.04
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.28%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.3%
ROA(5y)-59.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.27%
Cap/Sales 1.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.75
Quick Ratio 1.75
Altman-Z -3.98
F-Score6
WACC9.24%
ROIC/WACCN/A
Cap/Depr(3y)14.47%
Cap/Depr(5y)26.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.5%
EPS Next Y5.24%
EPS Next 2Y-0.06%
EPS Next 3Y14.3%
EPS Next 5Y5.95%
Revenue 1Y (TTM)N/A
Revenue growth 3Y743.98%
Revenue growth 5Y203.88%
Sales Q2Q%182.08%
Revenue Next Year-32.11%
Revenue Next 2Y-27.72%
Revenue Next 3Y31.06%
Revenue Next 5Y10.63%
EBIT growth 1Y42.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-172.31%
EBIT Next 3Y-15.13%
EBIT Next 5Y-23.95%
FCF growth 1Y65.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.37%
OCF growth 3YN/A
OCF growth 5YN/A